Windlas Biotech’s new injectable facility receives GMP certification
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
This approval reflects company’s unwavering commitment that the quality assurance
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Subscribe To Our Newsletter & Stay Updated